Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.
You may also be interested in...
Primary Care Focus Is Key To Bayer's Leading Position In China
Bayer Schering Pharma didn't become the number one health care company in China simply through the merger of Bayer and compatriot Schering AG in 2006. "The pure act of merging would not have been enough; we would only have been number six" in China, explains Liam Condon, managing Director of Bayer HealthCare China, which reported 2008 sales of over $750 million and over 50 percent growth
Primary Care Focus Is Key To Bayer's Leading Position In China
Bayer Schering Pharma didn't become the number one health care company in China simply through the merger of Bayer and compatriot Schering AG in 2006. "The pure act of merging would not have been enough; we would only have been number six" in China, explains Liam Condon, managing Director of Bayer HealthCare China, which reported 2008 sales of over $750 million and over 50 percent growth
Bayer’s Asia Pacific Regional Head Chris Lee On Bayer’s New Global R&D Center In Beijing And China’s Rising 21st Century Importance: An Interview With PharmAsia News
Bayer Schering Pharma Asia Pacific's Regional Head Chris Lee recently discussed with PharmAsia News' China Bureau Bayer's plans to create a new €100 million research and development center in Beijing and China's strengthening role in the company's 21st century blueprints for expansion. Bayer Schering's first global R&D center in Asia is slated to be operational by 2010, and will be the third in a triumvirate of research outposts that Bayer oversees worldwide (PharmAsia News, Feb. 19, 2009).